Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients

• Status: Completed
• Trial end date: 2006-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to determine if an intervention with a fracture manager to arrange bone densitometry after a hip fracture is more effective in diagnosing and treating osteoporosis when compared to "usual care". "Usual care" consists of no intervention to arrange bone mineral density (BMD) testing or therapy other than what normally occurs in the community. The investigators postulate that a fracture manager will be more effective in getting BMD done and in starting appropriate therapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Alberta
• Collaborator: Alberta Heritage Foundation for Medical Research
• Treatments: Alendronate; Risedronate Sodium; Risedronic Acid

Criteria

Inclusion Criteria:

• Ages 50 or over; males or females.

• Reside in the community or have access to bone densitometry

• Hip fracture

• Patient can consent or proxy consent available

• No contraindications to bisphosphonates

Exclusion Criteria:

• Patient refuses consent process

• Already receiving active drug therapy for osteoporosis other than calcium and vitamin D

• Dementia or delirium

• Pathological fracture

• Chronic corticosteroid therapy